
Join to View Full Profile
200 UCLA Medical Plz# UnivLos Angeles, CA 90095
Phone+1 310-824-2448
Fax+1 310-825-2572
Are you Dr. Volkmann?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Elizabeth Volkmann, MD is a rheumatologist in Los Angeles, California. She is currently licensed to practice medicine in California. She is affiliated with Ronald Reagan UCLA Medical Center.
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Rheumatology, 2011 - 2013
- David Geffen School of Medicine at UCLAClass of 2008
Certifications & Licensure
- CA State Medical License 2010 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Publications & Presentations
PubMed
- 1 citationsClinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project.Sara Faghihi-Kashani, Akira Yoshida, Francisca Bozan, Giovanni Zanframundo, Davide Rozza
Arthritis & Rheumatology. 2025-04-01 - Are we ready for home spirometry for systemic sclerosis-associated ILD?Jessica Channick, Elizabeth R Volkmann
The Lancet. Rheumatology. 2025-03-01 - A scoping review of the epidemiology of systemic sclerosis and its organ manifestations: 2018-2024.Samuel D Good, Ju Young Lee, Robert E Johnson, Elizabeth R Volkmann
Current Opinion in Rheumatology. 2025-03-01
Press Mentions
- ILD in Rheumatic Diseases: Advice on Screening, Treating, and MonitoringMarch 6th, 2025
- Biomarker Changes in Systemic Sclerosis–Associated Lung Disease Predict Therapy ResponseJanuary 9th, 2025
- Precision Medicine Benefits Patients with Systemic SclerosisNovember 26th, 2024
- Join now to see all
Grant Support
- Identifying predictors of treatment response in systemic sclerosis-related interstitial lung diseaseUNIVERSITY OF CALIFORNIA LOS ANGELES2020–2025